Clinical Trial Update: SAbR For Oligometastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating stereotactic ablative radiotherapy for oligometastatic renal cell carcinoma is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Oligometastatic Renal Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING